| Vorinostat | IC50 | 69.0 [1] |
| Vorinostat | Ki | 10.0 [1] |
| Trichostatin A | IC50 | 8.5 [1] |
| Trichostatin A | Ki | 0.2 [1], 0.23 [2], 0.64 [3], 0.87 [4] |
| Entinostat | IC50 | 300.0 [1] |
| Entinostat | Ki | 22.0 [1] |
| Tubastatin A | IC50 | 14350.0 [1] |
| Tubastatin A | Ki | 3823.3 [1] |
| Mocetinostat | IC50 | 150.0 [1] |
| Mocetinostat | Ki | 9.0 [1] |
| Romidepsin | IC50 | 3.6 [1] |
| Romidepsin | Ki | 0.0 [1] |
| Panobinostat | IC50 | 2.5 [1] |
| Panobinostat | Ki | 0.54 [1], 1.0 [2], 2.5 [3], 3.0 [4] |
| Apicidin | IC50 | 22.0 [1] |
| Apicidin | Ki | 0.04 [1] |
| Dacinostat | IC50 | 8.0 [1] |
| Dacinostat | Ki | 0.55 [1], 0.6 [2] |
| Belinostat | IC50 | 20.0 [1] |
| Belinostat | Ki | 0.85 [1], 0.9 [2], 26.0 [3] |
| Tubacin | IC50 | 240.0 [1], 1400.0 [2] |
| Tubacin | Ki | 28.0 [1], 326.4 [2], 995.0 [3] |
| Tacedinaline | IC50 | 1090.0 [1] |
| Tacedinaline | Ki | 50.0 [1] |
| 4-Acetamido-N-(2-amino-5-thiophen-2-ylphenyl)benzamide | IC50 | 40.0 [1] |
| 4-Acetamido-N-(2-amino-5-thiophen-2-ylphenyl)benzamide | Ki | 0.2 [1] |
| Largazole | IC50 | 69.8 [1] |
| Ricolinostat | IC50 | 58.0 [1] |
| N-Hydroxy-1-(4-methoxybenzyl)-1H-indole-6-carboxamide | IC50 | 14410.0 [1] |
| N-(2-Aminophenyl)-4-[[[(2S)-3-(1H-indol-3-yl)-2-[(4-methoxybenzoyl)amino]propanoyl]amino]methyl]benzamide | IC50 | 34.5 [1] |
| N-[(2S)-3-(1H-Indol-3-yl)-1-oxo-1-[[4-(propylaminocarbamoyl)phenyl]methylamino]propan-2-yl]-4-methoxybenzamide | IC50 | 32.9 [1], 50.1 [2], 63.28 [3], 77.5 [4], 91.2 [5] |
| Quisinostat | IC50 | 0.11 [1] |
| Quisinostat | Ki | 0.03 [1], 0.48 [2], 7.3 [3] |
| HDAC6 Inhibitor | IC50 | 12.7 [1], 271.0 [2], 340.0 [3], 3567.0 [4] |
| 3-(4-Benzenesulfonylamino-phenyl)-N-hydroxy-acrylamide | IC50 | 200.0 [1] |
| 3-[4-(4-Methoxyphenylsulfonylamino)phenyl]-2-propenehydroximic acid | IC50 | 60.0 [1], 200.0 [2] |
| N-Hydroxy-8-(4-methoxyphenyl)-8-oxooctanamide | IC50 | 15.0 [1] |
| 3-[4-(Tosylamino)phenyl]-2-propenehydroxamic acid | IC50 | 300.0 [1] |
| 3-[4-(3,4-Dimethoxyphenylsulfonylamino)phenyl]-2-propenehydroximic acid | IC50 | 90.0 [1] |
| (E)-N-Hydroxy-3-[2-(2-phenylethyl)-1-(2-pyrrolidin-1-ylethyl)benzimidazol-5-yl]prop-2-enamide | IC50 | 29.0 [1], 35.0 [2], 52.0 [3] |
| (E)-N-Hydroxy-3-[2-(2-phenylethyl)-1-(2-pyrrolidin-1-ylethyl)benzimidazol-5-yl]prop-2-enamide | Ki | 11.0 [1] |
| [4-(4-Amino-biphenyl-3-ylcarbamoyl)-benzyl]-carbamic acid benzyl ester | IC50 | 17.0 [1], 58.0 [2], 1880.0 [3], 14500.0 [4] |
| (E)-3-[1-[3-(Dimethylamino)-2,2-dimethylpropyl]-2-(2-phenylethyl)benzimidazol-5-yl]-N-hydroxyprop-2-enamide | IC50 | 24.0 [1], 41.0 [2], 42.0 [3] |
| (E)-3-[1-[3-(Dimethylamino)-2,2-dimethylpropyl]-2-(2-phenylethyl)benzimidazol-5-yl]-N-hydroxyprop-2-enamide | Ki | 15.0 [1] |
| (E)-N-Hydroxy-3-[2-(2-phenylethyl)-1-(2-piperidin-1-ylethyl)benzimidazol-5-yl]prop-2-enamide | IC50 | 23.0 [1], 26.0 [2], 39.0 [3] |
| (E)-N-Hydroxy-3-[2-(2-phenylethyl)-1-(2-piperidin-1-ylethyl)benzimidazol-5-yl]prop-2-enamide | Ki | 12.0 [1] |
| Lovastatin | IC50 | 11214.0 [1], 11911.0 [2] |
| N-Hydroxybenzamide | IC50 | 4730.0 [1], 20000.0 [2] |
| Scriptaid | IC50 | 71.0 [1], 200.0 [2] |
| Scriptaid | Ki | 1.5 [1] |
| Chidamide | IC50 | 540.0 [1], 864.0 [2], 2700.0 [3] |
| Azumamide E | IC50 | 50.0 [1], 1220.0 [2] |
| Azumamide E | Ki | 67.0 [1] |
| CID 11427204 | IC50 | 48.0 [1], 96.0 [2] |
| Tert-butyl N-[(2S)-1-(cyclopentylamino)-1-oxo-7-sulfanylheptan-2-yl]carbamate | IC50 | 1210.0 [1], 1731.0 [2] |
| N-(4-Aminobiphenyl-3-yl)benzamide | IC50 | 52.0 [1], 60.0 [2], 410.0 [3] |
| Largazole Thiol | IC50 | 0.4 [1], 1.2 [2] |
| (8E)-N-Hydroxy-8-hydroxyimino-8-(4-phenylphenyl)octanamide | IC50 | 4.0 [1] |
| 3-[4-(Biphenyl-4-ylsulfamoyl)-phenyl]-N-hydroxy-acrylamide | IC50 | 40.0 [1] |
| 8-(Biphenyl-4-yl)-N-hydroxy-8-oxooctanamide | IC50 | 5.0 [1] |
| 3-[4-(4-Tert-Butyl-benzenesulfonylamino)-phenyl]-N-hydroxy-acrylamide | IC50 | 100.0 [1], 200.0 [2] |
| N-Hydroxy-8-(naphthalen-2-yl)oct-7-enamide | IC50 | 6.0 [1] |
| (8E)-N-Hydroxy-8-hydroxyimino-8-naphthalen-2-yloctanamide | IC50 | 8.5 [1] |
| N-Hydroxy-7-oxo-7-phenylheptanamide | IC50 | 500.0 [1] |
| N-Hydroxy-8-oxo-8-[4-(trifluoromethyl)phenyl]octanamide | IC50 | 45.0 [1] |
| N-Hydroxy-6-oxo-6-phenylhexanamide | IC50 | 1500.0 [1] |
| N,8-Dihydroxy-8-(naphthalen-2-yl)octanamide | IC50 | 35.0 [1] |
| 8-Oxo-8-phenyl-octanoic acid hydroxyamide | IC50 | 65.0 [1] |
| 8-(4-Bromophenyl)-N-hydroxy-8-oxooctanamide | IC50 | 45.0 [1] |
| N-Hydroxy-8-oxo-8-(pyridin-3-yl)octanamide | IC50 | 153.0 [1] |
| N-Hydroxy-9-oxo-9-phenylnonanamide | IC50 | 135.0 [1] |
| N-(2-Amino-phenyl)-nicotinamide | IC50 | 2600.0 [1], 2630.0 [2], 12400.0 [3] |
| N-Hydroxy-8-(2-methoxyphenyl)-8-oxooctanamide | IC50 | 95.0 [1] |
| N-Hydroxy-8-(naphthalen-2-yl)non-8-enamide | IC50 | 8.0 [1] |
| N-Hydroxy-8-(naphthalen-2-yl)octanamide | IC50 | 25.0 [1] |
| N-(2-Aminophenyl)-4-[(3,4-dimethoxyanilino)methyl]benzamide | IC50 | 440.0 [1], 2000.0 [2] |
| N-[(2S)-1,8-Dioxo-1-[(4-phenyl-1,3-thiazol-2-yl)amino]nonan-2-yl]-1-methylpiperidine-2-carboxamide | IC50 | 55.0 [1] |
| Azumamide C | IC50 | 1170.0 [1] |
| Azumamide C | Ki | 20.0 [1], 32.0 [2] |
| 4-(Phenylsulfonylamino)benzenebutanehydroximic acid | IC50 | 1000.0 [1] |
| 3-(4-Benzenesulfonylamino-phenyl)-N-hydroxy-2-methyl-propionamide | IC50 | 17000.0 [1] |
| CID 24853793 | IC50 | 27.0 [1], 59.0 [2] |
| CID 24857909 | IC50 | 580.0 [1] |
| CID 25023797 | IC50 | 890.0 [1], 1800.0 [2] |
| CID 25023798 | IC50 | 5000.0 [1], 5300.0 [2] |
| 4-(Phenylsulfonylamino)benzenepropanehydroximic acid | IC50 | 100.0 [1] |
| N-Hydroxy-6-[(2S,5S,8S,11S)-8-(1H-indol-3-ylmethyl)-2-methyl-11-(2-methylpropyl)-3,6,9,13-tetraoxo-1,4,7,10-tetrazacyclotridec-5-yl]hexanamide | IC50 | 2.0 [1] |
| 6-[(2S,5S,8S,11S)-2-Methyl-11-(2-methylpropyl)-8-(naphthalen-1-ylmethyl)-3,6,9,13-tetraoxo-1,4,7,10-tetrazacyclotridec-5-yl]hexanoic acid | IC50 | 200.0 [1] |
| 3-[4-(Biphenyl-4-sulfonylamino)-phenyl]-N-hydroxy-acrylamide | IC50 | 10.0 [1] |
| 3-(4-Benzenesulfonylamino-phenyl)-N-hydroxy-2-methyl-acrylamide | IC50 | 2000.0 [1] |
| 3-[4-(Benzenesulfonyl-methyl-amino)-phenyl]-N-hydroxy-acrylamide | IC50 | 570.0 [1], 600.0 [2] |
| 8-[4-(4-Bromophenyl)phenyl]-N-hydroxy-8-oxooctanamide | IC50 | 2.0 [1] |
| N-(2-Amino-phenyl)-3-[4-(3,4-dimethoxy-benzenesulfonylamino)-phenyl]-acrylamide | IC50 | 4000.0 [1] |
| N-(2-Amino-phenyl)-3-[4-(biphenyl-4-sulfonylamino)-phenyl]-acrylamide | IC50 | 1000.0 [1] |
| N-(2-Amino-phenyl)-3-[4-(biphenyl-4-ylsulfamoyl)-phenyl]-acrylamide | IC50 | 1000.0 [1], 1200.0 [2] |
| N-(2-Amino-phenyl)-3-[4-(3,4-dimethoxy-phenylsulfamoyl)-phenyl]-acrylamide | IC50 | 2300.0 [1], 3000.0 [2] |
| N-Hydroxy-3-(4-p-tolylsulfamoyl-phenyl)-acrylamide | IC50 | 50.0 [1], 200.0 [2] |
| N-(2-Amino-phenyl)-3-(4-p-tolylsulfamoyl-phenyl)-acrylamide | IC50 | 1500.0 [1], 2000.0 [2] |
| 3-[4-(3,4-Dimethoxy-phenylsulfamoyl)-phenyl]-N-hydroxy-acrylamide | IC50 | 50.0 [1], 60.0 [2] |
| 3-{4-[3-(3,4-Dimethoxy-phenyl)-ureido]-phenyl}-N-hydroxy-acrylamide | IC50 | 480.0 [1], 1000.0 [2] |